STUDY ON SAFETY OF INSULIN ADD ON THERAPY AND ORAL HYPOGLYCEMIC AGENTS (OHGAs) IN TYPE - II DIABETES PATIENTS

STUDY ON SAFETY OF INSULIN ADD ON THERAPY AND ORAL HYPOGLYCEMIC AGENTS (OHGAs) IN TYPE - II DIABETES PATIENTS

  • D.Ashalatha Pharm.D V year of Jagan’s institute of pharmaceutical science, spsp Nellore, Andhra Pradesh,India.
  • C.Roop kumar Pharm.D V year of Jagan’s institute of pharmaceutical science, spsp Nellore, Andhra Pradesh,India.
  • K.Prem Raj Pharm.D V year of Jagan’s institute of pharmaceutical science, spsp Nellore, Andhra Pradesh,India.
  • V.Vani Pharm.D V year of Jagan’s institute of pharmaceutical science, spsp Nellore, Andhra Pradesh,India.
  • Narayana swamy Palyam Department of Pharmacy Practice, Jagan’s institute of pharmaceutical science, spsp Nellore, Andhra Pradesh,India.
  • Sankara Lakshmikanth PTO(Senior Technical Assistant), NIN, Telangana, National TB Prevelence Survey,ICMR-NIRT.
    drlakshmikanth08@gmail.com

Abstract

Objectives: A clinical observational investigation directed to look at the security of Insulin add-on treatment and  Hypoglycemic Agents in polypharmacy and to advance safe utilization of insulin and hypoglycemic agents in Type II Diabetes patients, through patient guiding by Clinical drug specialist at Jayabharath hospital, Nellore.


Methods: A Prospective Observational investigation was directed on Type -2 Diabetes mellitus patients in the General Medicine office in a tertiary consideration emergency clinic, during the time of June – December 2019. The work was completed by utilizing quiet information assortment structures and a Diabetes survey.


Results: Among 193 investigation populace with Type -2 Diabetes, hypoglycemic agents in polypharmacy 46.25% (n=108) was discovered to be more than Insulin alone, and Insulin add on treatment. Conclusion: From the examination, it was discovered that patients who are on hypoglycemic agents in polypharmacy were exposed to GI unsettling influences and who are on Insulin treatment was exposed to hypoglycemic scenes. Considering the key job of drug specialists the security of antidiabetic prescriptions and adherence was improved through patient directing.     

Keywords: Insulin, Hypoglycemic agents, type-2 DM

Downloads

Download data is not yet available.

References

1. King, P.; Peacock, I.; Donnelly, R. Intensive Blood-Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352 (9131), 837–853.

2. Stratton, I. M.; Adler, A. I.; Neil, H. A.; Matthews, D. R.; Manley, S. E.; Cull, C. A.; Hadden, D.; Turner, R. C.; Holman, R. R. Association of Glycaemia with Macrovascular and Microvascular Complications of type 2 Diabetes (UKPDS 35): Prospective Observational Study. BMJ 2000, 321 (7258), 405–412.

3. Del Prato, S.; Felton, A. M.; Munro, N.; Nesto, R.; Zimmet, P.; Zinman, B.; Global Partnership for Effective Diabetes Management Improving Glucose Management: Ten Steps to Get More Patients with type 2 Diabetes to Glycaemic Goal. Recommendations from the Global Partnership for Effective Diabetes Management. Int. J. Clin. Pract. Suppl. 2007, 157 (157), 47–57.

4. Tibaldi, J.; Rakel, R. E. Why, When and How to Initiate Insulin Therapy in Patients with type 2 Diabetes. Int. J. Clin. Pract. 2007, 61 (4), 633–644.

5. Freeman, J. S. Insulin Analog Therapy: Improving the Match with Physiologic Insulin Secretion. J. Am. Osteopath. Assoc. 2009, 109 (1), 26–36.

6. Andayani, T. M.; Ibrahim, M. I. M.; Asdie, A. H. The Safety of Triple Therapy with Oral Antidiabetics Versus Insulin in Type 2 Diabetes. Asian J. Pharm. Clin. Res. 2010, 3, 201–203.

7. Whiting, D. R.; Guariguata, L.; Weil, C.; Shaw, J. IDF Diabetes Atlas: Global Estimates of the Prevalence of Diabetes for 2011 and 2030. Diabetes Res. Clin. Pract. 2011, 94 (3), 311–321.
C. Powers, Harrison’s principles of internal medicine, Chapter 338, Diabetes Mellitus, 17th edition, New York: McGraw Hill; 2008; 2275-2304.

8. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comphrehensive Review AACE Diabetes Care Plan Guidelines. Endocr. Pract. 2011, 17 (2).

9. American Diabetes Association Standards of Medical Care in diabetes—2014. Diabetes Care 2014, 37 (1), S14–S80.

10. Api, I. C. P. guidelines on diabetes. http://www.japi.org/july2007/IDGM.pdf (accessed 2/9/2020).

11. International Diabetes Federation (IDF) [Internet]. Country Estimates Table 2011. IDF- Diabetes Atlas, 6th ed.

12. Noncommunicable Diseases in the Southeast Asia Region, Situation and Response. http://apps.searo.who.int/PDS_DOCS/B4793.pdf; World Health Organization, 2011 (accessed 2/9/2020).


13. Issue3, December2011, Pages311.available at: http://www.sciencedirect.com/science/article/pii/S0168822711005912.


14. IDF Diabetes Atlas.‖ International diabetes federation. March 2013. http://www.idf.org/diabetesatlas


15. Chiara di loreto, MD et al, Validation of a Counseling Strategy to Promote the Adoption and the maintenance of physical activity by Type 2 diabetic subjects, diabetes care, volume 26, number 2, 404-408, February 2003.


16. Jaakko tuomilehto, MD,et.al, Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance, the new England journal of medicine, volume 344, may 3, 2001.


17. Vermeire EIJJ,et.al, Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus, The Cochrane library, 2001, issue-1, Published by JohnWiley & Sons, Ltd.


18. Hae Mi Choe, PharmD; Sonya Mitrovich, MD; Proactive Case Management of High-risk Patients With Type 2 Diabetes Mellitus by a Clinical Pharmacist:A Randomized Controlled Trial, American journal of managed care, vol.11, no:4,253-260, april 2005


19. Marita poskiparta, kirsti kasila, Dietary and physical activity counselling on type 2 diabetes and impaired glucose tolerance by physicians and nurses in primary healthcare in Finland, Scandinavian Journal of Primary Health Care, 2006; 24: 206-210 .


20. Nadia Rashid Al Mazroui, Mostafa Mohamed Kamal, Influence of pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus, British Journal of Clinical Pharmacology, Volume 67, Issue 5, pages 547–557, May 2009.


21. anjay kaul, ann F. Bolger, David Herrington et.al, thiazolidine diones and cardiovascular risks: a science advisory from the American heart association and American college of cardiology foundation, journal of American heart association, February 23, 2010; 121: 1868-1877.


22. Stephen M.setter, pharm D, metformin hydrochloride in the treatment of diabetes mellitus: a clinical review with a focus on dual therapy, clinical therapeutics, volume 25, issue 12, p: 2991-3026, December 2003.


23. Saenz a, fernandez-esteban, metformin monotherapy for type-2 diabetes mellitus, Cochrane library 2005, issue 3.


24. Meenu Rani, ShaileshYadav, Incidence of Hypoglycemia and Other Side Effects in Patients of Type 2 Diabetes Mellitus Treated with Glimepiride versus Glibenclamide,international journal of health sciences and research, p:68-72, Vol.4; Issue: 2; February 2014.

25. Markolfhanefeld, MD, PHD, One-year glycemic control with asulfonylurea plus pioglitazone versus asulfonylurea plus metformin in patients with type 2 diabetes, diabetes care, p: 141-147, volume 27, number 1, january 2004.

26. Davidson J, Vexiau P, Cucinotta D, Vaz J, Kawamori R. Biphasic insulin aspart 30: literature review ofadverse events associated with treatment. Clinical Therapeutics 2005; 27 (Supplement B): S7 5-S88. [PubMed: 16519039]
Statistics
28 Views | 11 Downloads
Citatons
How to Cite
D.Ashalatha, D., C. kumar C.Roop kumar, K. R. K.Prem Raj, V. V.Vani, narayana swamy palyam, and S. L. Sankara Lakshmikanth. “STUDY ON SAFETY OF INSULIN ADD ON THERAPY AND ORAL HYPOGLYCEMIC AGENTS (OHGAs) IN TYPE - II DIABETES PATIENTS : STUDY ON SAFETY OF INSULIN ADD ON THERAPY AND ORAL HYPOGLYCEMIC AGENTS (OHGAs) IN TYPE - II DIABETES PATIENTS ”. World Journal of Current Medical and Pharmaceutical Research, Sept. 2020, pp. 301-6, doi:10.37022/wjcmpr.vi.155.
Section
Research Articles